参桃软肝丸对术后复发性肝癌的治疗作用

Effect of Shen Tao Ruangan Pill for Postoperative Recurred Liver Cancer

【目的】通过随机、对照研究方法,观察中药复方参桃软肝丸(主要由茵陈、白花蛇舌草、半枝莲、莪术、桃仁、当归、丹参、生晒参、茯苓、龟板组成)对术后复发性肝癌的治疗效果,评估参桃软肝丸治疗肝癌术后复发的临床疗效。【方法】将符合入选标准的40例原发性肝癌术后复发的患者随机分为治疗组和对照组,各组患者20例。治疗组在一般治疗、对症治疗基础上加服参桃软肝丸,对照组在一般治疗、对症治疗基础上加服平消胶囊,治疗3个月后对各项指标进行比较。【结果】(1)临床症状缓解情况:治疗后两组患者的临床症状均得到一定程度的改善,且治疗组在腹胀、纳呆、乏力等症状的改善方面优于对照组(P<0.05)。(2)在卡氏评分分级、肝脏储备功能改善方面治疗组优于对照组,差异具有显著性意义(P<0.05)。治疗组与对照组血中甲胎蛋白下降水平、瘤体变化的差异均无显著性意义(P>0.05)。(3)治疗组与对照组的无进展生存期分别为(172±11.64)d、(143±10.95)d;治疗组3个月、半年、10个月生存率分别为82.31%、70.42%、50.33%,对照组相应的生存率分别为72.70%、65.70%、46.33%,两组患者中位生存时间分别为(203±20.87)d、(167±19.58)d,经检验两者具有显著性差异(P<0.05)。【结论】参桃软肝丸能改善原发性肝癌术后复发患者的临床症状及机体功能状态和肝脏储备功能,有效稳定瘤体,延长患者的无进展生存期和中位生存期。

[ Objective] To investigate the therapeutic effect of Shen Tao Ruangan Pill （STRP） for postoperative recurred liver cancer by a randomized and controlled trial. [ Methods] Forty patients with postoperative recurred liver cancer were equally randomized into groups A and B. The two groups received routine symptomatic treatment, and group A was additionally treated with STRP （mainly composed of Herba Artemisiae Scopariae, Herba Hedyotis Diffusae, Herba Seutellariae Barbatae, Rhizoma Cureumae, Semen Persieae, Radix Angelieae Sinensis, Radix Salviae Mihiorrhizae, Radix Ginseng, Poria, Carapax et Plastrum Testudinis） and group B with Pingxiao Capsule. After 3- month treatment, the therapeutic effect was evaluated in the two groups. [ Results] （1） After treatment, the symptoms were relieved in both of groups A and B, and group A had a better effect in relieving abdominal distention, anorexia and lassitude than group B （ P 〈 0.05）. （2） Grading of Karnofsky scores and hepatic reserved function in group A were superior to those in group B, the difference being significant （P 〈 0.05）. The differences of alpha-fetoprotein （AFP） decrease and the change of tumor mass were insignificant between groups A and B （P 〉 0.05）. （3） The non-progressive survival period was （172± 11.64） days in group A and （143 ± 10.95） days in group B; the survival rate within 3, 6 and 10 months was 82.31%, 70.42% and 50.33% in group A respectively, and 72.70%, 65.70% and 46.33% in group B respectively; the median survival time was （203 ± 20.87） days in group A and （167 ± 19.58） days in group B, the difference being significant （ P 〈 0.05）. [ Conclusion] STRP is effective in relieving symptoms, improving body function and hepatic reserved function, counteracting tumor growth, and prolonging the non-progressive survival period and the median survival time for postoperative recurrence in primary liver cancer.